134 related articles for article (PubMed ID: 37137837)
1. [Antisense oligodeoxynucleotides: the certain but limited efficacy and the uncovering mechanisms for the cure of chronic hepatitis B].
Li DY; Lu DJ; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):192-197. PubMed ID: 37137837
[TBL] [Abstract][Full Text] [Related]
2. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
[TBL] [Abstract][Full Text] [Related]
3. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.
Cremer J; Elston R; Campbell FM; Kendrick S; Paff M; Quinn G; Theodore D
Adv Ther; 2023 Sep; 40(9):4101-4110. PubMed ID: 37393402
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
[TBL] [Abstract][Full Text] [Related]
5. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Expert Opin Investig Drugs; 2023; 32(11):971-983. PubMed ID: 37902953
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
Yuen MF; Lim SG; Plesniak R; Tsuji K; Janssen HLA; Pojoga C; Gadano A; Popescu CP; Stepanova T; Asselah T; Diaconescu G; Yim HJ; Heo J; Janczewska E; Wong A; Idriz N; Imamura M; Rizzardini G; Takaguchi K; Andreone P; Arbune M; Hou J; Park SJ; Vata A; Cremer J; Elston R; Lukić T; Quinn G; Maynard L; Kendrick S; Plein H; Campbell F; Paff M; Theodore D;
N Engl J Med; 2022 Nov; 387(21):1957-1968. PubMed ID: 36346079
[TBL] [Abstract][Full Text] [Related]
7. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B].
Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
[TBL] [Abstract][Full Text] [Related]
9. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
10. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
11. RNA interference as a novel treatment strategy for chronic hepatitis B infection.
Hui RW; Mak LY; Seto WK; Yuen MF
Clin Mol Hepatol; 2022 Jul; 28(3):408-424. PubMed ID: 35172540
[TBL] [Abstract][Full Text] [Related]
12. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
13. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment.
Yuen MF; Wong DK; Schluep T; Lai CL; Ferrari C; Locarnini S; Lo RC; Gish RG; Hamilton J; Wooddell CI; Mak LY; Given BD
Gut; 2022 Apr; 71(4):789-797. PubMed ID: 33712437
[TBL] [Abstract][Full Text] [Related]
14. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
15. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2022 Aug; 6(8):1870-1880. PubMed ID: 35368148
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2021 Nov; 5(11):1873-1887. PubMed ID: 34558823
[TBL] [Abstract][Full Text] [Related]
17. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
[TBL] [Abstract][Full Text] [Related]
18. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
[TBL] [Abstract][Full Text] [Related]
19. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
Seto WK; Liu KS; Mak LY; Cloherty G; Wong DK; Gersch J; Lam YF; Cheung KS; Chow N; Ko KL; To WP; Fung J; Yuen MF
Gut; 2021 Apr; 70(4):775-783. PubMed ID: 32759300
[TBL] [Abstract][Full Text] [Related]
20. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
